Learning chapters
Prefer to test your knowledge rather than reading journals? Complete our chapters and mini-quizzes today to enhance your attitude, skills and knowledge in oncology biosimilars.
![Protein biology and biologic medications](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1301300910-1024x439.jpg)
CHAPTER 1
Protein biology and biologic medications
Discussing the fundamentals of protein synthesis - a process that produces some of the most used biologics and their biosimilars
![Biologic and biosimilar manufacture](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1268181219-1024x439.jpg)
CHAPTER 2
Biologic and biosimilar manufacture
Covering development and manufacture of a biologic or biosimilar, inherent variability and quality management
![Biologic product stability – background theory](https://ask-biosimilars.com/wp-content/uploads/2021/07/gettyimages-1291055173-170667a.jpg)
CHAPTER 3
Biologic product stability – background theory
Detailing the types of factors affecting stability and degradation of biologics and biosimilars, and the studies used to measure
![Interpretation of stability data](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-526543516-1024x439.jpg)
CHAPTER 4
Interpretation of stability data
Describing factors to consider for interpretation of stability and the associated data
![Excipients](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1151449218-1024x439.jpg)
CHAPTER 5
Excipients
Including reasons for use and classification of excipients and how they maintain biologic or biosimilar stability and integrity
![Approving a biosimilar](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1223362514-1024x439.jpg)
CHAPTER 6
Approving a biosimilar
Summarising the regulatory principles underlying biosimilar approval and how this differs from the reference biopharmaceutical and small molecule generics
![Immunogenicity](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1218459794-1024x439.jpg)
CHAPTER 7
Immunogenicity
Discussing factors effecting immunogenicity and resultant safety and efficacy of a biopharmaceutical
![Pharmacovigilance](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1055095222-1024x439.jpg)
Chapter 8
Pharmacovigilance
Evaluating why pharmacovigilance is essential to characterise the safety and efficacy of biopharmaceuticals and biosimilars
![Biosimilars in practice](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1217841921-1024x439.jpg)
Chapter 9
Biosimilars in practice
Detailing what to consider when reviewing a biosimilar for inclusion in a formulary and the role of pharmacists in implementing biosimilars into the health service
![Patient considerations and communication](https://ask-biosimilars.com/wp-content/uploads/2021/07/GettyImages-1278412677-1024x439.jpg)
chapter 10
Patient considerations and communication
Discussing the educational needs of patients about biosimilars and the pharmacists’ role in delivering advice and support to patients taking biosimilars
Other educational activities
![](https://ask-biosimilars.com/wp-content/uploads/2022/11/i_abstract.png)
Real world evidence: Abstract library
Summaries of the latest published papers, data and real-world evidence
![](/wp-content/themes/cogora/assets/images/flag-new-top.png)
![](https://ask-biosimilars.com/wp-content/uploads/2022/11/i_soon-1.png)
Real word evidence: case studies
Regional case studies reflecting on the adoption of oncology biosimilars
![](/wp-content/themes/cogora/assets/images/flag-new-top.png)
![](https://ask-biosimilars.com/wp-content/uploads/2022/11/webinars.png)
Expert webinars
Watch experts discuss using biosimilars with real-world cases